主页 > 医药生命 >
【bio-news】干细胞专利风烟云起,科学家长征继续
February 28, 2008, 4:23 pm
As Stem Cell Patent Fight Lingers, Science Marches On
The patent office just upheld a key embryonic stem cell patent, the latest turn in a long fight over some intellectual property that’s central to the whole field. The fight is far from over — indeed, it’s likely to drag out for so long that lots of other patents may be more important than those at issue by the time the dust settles, according to one IP expert the Health Blog talked to this afternoon.
The fight centers on three patents are held by the Wisconsin Alumni Research Foundation (that’s WARF to you), the result of work done by UW researcher James Thomson. Geron, a company trying to develop human therapies based on embryonic stem cells, says it holds certain exclusive licenses on the patents.
The Public Patent Foundation argues the patents should be invalidated, and has won some legal battles in the larger war. But WARF and Geron are still able enforce the patents. And by the time the whole process wraps up, the IP questions could be largely moot, according to Ken Taymor, who runs the Center for Law, Business and the Economy at UC Berkeley.
It’ll be several years before the patent fight shakes out, according to Taymor, who co-authored a recent article on the subject in the journal Cell Stem Cell. “In the mean time, there is all this other patenting activity that’s going on — patenting activity that’s not being challenged,” he said. “Those are essential steps for commercialization.”
What’s more, Geron and WARF hold a lot of the newer stem cell patents. “So the more interesting question,” Taymor said, “is what patents do they hold and what’s the scope of the claims that they have downstream in commercialization?” Taymor and his colleagues are looking into that now, and plan to publish their findings. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 February 28, 2008, 4:23 pm
As Stem Cell Patent Fight Lingers, Science Marches On
当干细胞专利战争徘徊不前的时候，科学的步伐继续前进
The patent office just upheld a key embryonic stem cell patent, the latest turn in a long fight over some intellectual property that’s central to the whole field. The fight is far from over — indeed, it’s likely to drag out for so long that lots of other patents may be more important than those at issue by the time the dust settles, according to one IP expert the Health Blog talked to this afternoon.
专利局刚刚批准了一项重要的胚胎干细胞专利，这是在对整个领域都至关重要的知识产权问题上的长期战争的最新转折。其实，战争远没有结束，根据今天下午一个与健康博客谈话的知识产权专家称，它可能拖延很久，到时大量其他专利可能会比那些在沉埃落定前都争论不休的专利更为重要。
The fight centers on three patents are held by the Wisconsin Alumni Research Foundation (that’s WARF to you), the result of work done by UW researcher James Thomson. Geron, a company trying to develop human therapies based on embryonic stem cells, says it holds certain exclusive licenses on the patents.
战争集中于3项专利，分别是威斯康辛校友研究基金（WARF）所持专利，由UW研究者James Thomson完成的工作结果，以及一个尝试研发基于胚胎干细胞人类治疗的公司Geron。Geron说，它在该专利上持有确定而绝对的许可证。
The Public Patent Foundation argues the patents should be invalidated, and has won some legal battles in the larger war. But WARF and Geron are still able enforce the patents. And by the time the whole process wraps up, the IP questions could be largely moot, according to Ken Taymor, who runs the Center for Law, Business and the Economy at UC Berkeley.
公共专利基金辩证说，这些专利应被视为无效，公共专利基金已在更大规模的战争中取得了合法的胜利。但是WARF和Geron仍能够坚持他们的专利。根据Ken Taymor说，到整个过程结束的的时候，知识产权问题才能够拿出来讨论。Taymor在UC Berkeley为法律、商业和经济运作了公共专利基金中心。
It’ll be several years before the patent fight shakes out, according to Taymor, who co-authored a recent article on the subject in the journal Cell Stem Cell. “In the mean time, there is all this other patenting activity that’s going on — patenting activity that’s not being challenged,” he said. “Those are essential steps for commercialization.”
根据Taymor说，还有好几年时间专利战争才能落地。Taymor在近期《细胞干细胞》杂志发表的一篇文章里是共同作者。“在这期间，所有其他的专利活动还在继续行进，专利活动没有因此受到挑战。”他说，“这是迈向商业化的重要步伐”。
What’s more, Geron and WARF hold a lot of the newer stem cell patents. “So the more interesting question,” Taymor said, “is what patents do they hold and what’s the scope of the claims that they have downstream in commercialization?” Taymor and his colleagues are looking into that now, and plan to publish their findings.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-19 17:14
医学,生命科学网